Outlook Therapeutics Management
Management criteria checks 2/4
Outlook Therapeutics' CEO is Larry Kenyon, appointed in Sep 2015, has a tenure of 9.25 years. directly owns 0.025% of the company’s shares, worth $8.74K. The average tenure of the management team and the board of directors is 4.5 years and 6.3 years respectively.
Key information
Larry Kenyon
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 9.3yrs |
| CEO ownership | 0.03% |
| Management average tenure | 4.5yrs |
| Board average tenure | 6.3yrs |
Recent management updates
Recent updates
Is Outlook Therapeutics (NASDAQ:OTLK) Using Debt In A Risky Way?
Nov 03
Outlook Therapeutics resubmits application for eye disease wAMD drug, shares rise 8%
Aug 30Outlook Therapeutics GAAP EPS of -$0.08 misses by $0.01
Aug 10Is Outlook Therapeutics (NASDAQ:OTLK) Using Too Much Debt?
Jul 06Outlook Therapeutics announces full cash pre-payment of convertible promissory note
Jul 05Outlook Therapeutics: A One-Buck Lottery Ticket
Jun 09Is Outlook Therapeutics (NASDAQ:OTLK) Using Debt Sensibly?
Apr 01CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$94m |
| Mar 31 2024 | n/a | n/a | -US$159m |
| Dec 31 2023 | n/a | n/a | -US$51m |
| Sep 30 2023 | n/a | n/a | -US$59m |
| Jun 30 2023 | n/a | n/a | -US$60m |
| Mar 31 2023 | n/a | n/a | -US$57m |
| Dec 31 2022 | n/a | n/a | -US$70m |
| Sep 30 2022 | n/a | n/a | -US$66m |
| Jun 30 2022 | n/a | n/a | -US$65m |
| Mar 31 2022 | n/a | n/a | -US$60m |
| Dec 31 2021 | n/a | n/a | -US$53m |
| Sep 30 2021 | US$3m | US$425k | -US$53m |
| Jun 30 2021 | n/a | n/a | -US$50m |
| Mar 31 2021 | n/a | n/a | -US$40m |
| Dec 31 2020 | n/a | n/a | -US$45m |
| Sep 30 2020 | US$1m | US$425k | -US$49m |
| Jun 30 2020 | n/a | n/a | -US$49m |
| Mar 31 2020 | n/a | n/a | -US$51m |
| Dec 31 2019 | n/a | n/a | -US$45m |
| Sep 30 2019 | US$2m | US$425k | -US$36m |
| Jun 30 2019 | n/a | n/a | -US$38m |
| Mar 31 2019 | n/a | n/a | -US$43m |
| Dec 31 2018 | n/a | n/a | -US$40m |
| Sep 30 2018 | US$716k | US$372k | -US$48m |
Compensation vs Market: Insufficient data to establish whether Larry's total compensation is reasonable compared to companies of similar size in the US market.
Compensation vs Earnings: Larry's compensation has increased whilst the company is unprofitable.
CEO
Larry Kenyon (58 yo)
9.3yrs
Tenure
Mr. Lawrence A. Kenyon, also known as Larry, CPA, serves as Executive Vice President, Chief Financial Officer, Treasurer and Corporate Secretary of Outlook Therapeutics, Inc. since July 06, 2021. He serves...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 6.7yrs | US$242.50k | 0.0025% $ 872.8 | |
| EVP, CFO | 9.3yrs | no data | 0.025% $ 8.7k | |
| Chief Commercial Officer | 6.1yrs | US$718.20k | 0.16% $ 54.8k | |
| Senior Vice President of Licensing and M&A | 2.8yrs | no data | no data | |
| Senior Vice President of Medical Affairs | 1.9yrs | no data | no data | |
| Senior Vice President of Clinical Development & Regulatory Affairs | no data | no data | no data | |
| Senior VP - Head of Europe | 1.1yrs | no data | no data |
4.5yrs
Average Tenure
58yo
Average Age
Experienced Management: OTLK's management team is considered experienced (4.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 6.7yrs | US$242.50k | 0.0025% $ 872.8 | |
| EVP, CFO | 6.3yrs | no data | 0.025% $ 8.7k | |
| Independent Director | 9yrs | US$95.00k | 0.10% $ 34.8k | |
| Independent Director | 2.3yrs | US$79.00k | 0% $ 0 | |
| Independent Non-Employee Director | 4.7yrs | US$112.50k | 0% $ 0 | |
| Board Observer | no data | no data | no data | |
| Independent Non-Employee Director | 4.7yrs | US$79.00k | 0% $ 0 | |
| Independent Director | 7.3yrs | US$113.00k | 0.014% $ 5.0k | |
| Independent Director | 7.2yrs | US$110.00k | 0.013% $ 4.7k | |
| Independent Director | 4.5yrs | US$75.00k | 0% $ 0 |
6.3yrs
Average Tenure
61yo
Average Age
Experienced Board: OTLK's board of directors are considered experienced (6.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/24 15:09 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Outlook Therapeutics, Inc. is covered by 12 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Edward Woo | Ascendiant Capital Markets LLC |
| Brian Kemp Dolliver | Brookline Capital Markets |
| Kumaraguru Raja | Brookline Capital Markets |